Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,890 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Patients Clear all
Terminated Phase 2 Interventional

Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy

NCT00448097
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
cetuximab, docetaxel
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 29, 2026, 11:25 AM EDT
Withdrawn No phase listed Observational

Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)

NCT03296124
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 29, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

NCT03365791
View directory record Official record
Conditions
Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma, Soft Tissue Sarcoma, Ovarian Adenocarcinoma, Advanced Well-differentiated Neuroendocrine Tumors, Diffuse Large B Cell Lymphoma
Interventions
PDR001, LAG525
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
San Francisco, California • Port Saint Lucie, Florida • Athens, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 29, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

NCT00111618
View directory record Official record
Conditions
Prostate Cancer
Interventions
AS1404 (DMXAA)
Drug
Lead sponsor
Antisoma Research
Industry
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Alhambra, California • Bakersfield, California • Burbank, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2009 · Synced Oct 29, 2026, 11:25 AM EDT
Not listed Phase 1 Interventional

Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients

NCT02058680
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA/IL-2/GM-CSF
Biological
Lead sponsor
OncBioMune Pharmaceuticals
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 29, 2026, 11:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Carbon-11 Labeled Sarcosine in Prostate Cancer

NCT02462447
View directory record Official record
Conditions
Prostate Cancer
Interventions
11C-sarcosine, 11C-choline
Drug
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 29, 2026, 11:25 AM EDT
Completed Early Phase 1 Interventional Results available

Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

NCT03507608
View directory record Official record
Conditions
Prostate Cancer
Interventions
Flutamide, Placebo
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 29, 2026, 11:25 AM EDT
Completed Phase 1 Interventional

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

NCT03123978
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Enzalutamide, Niclosamide
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
19 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 29, 2026, 11:25 AM EDT
Completed No phase listed Observational

Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis

NCT02457715
View directory record Official record
Conditions
Prostate Cancer, Renal Cancer, Brain Cancer, ALS
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 29, 2026, 11:25 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

NCT04879940
View directory record Official record
Conditions
Prostate Carcinoma, Benign Prostatic Hyperplasia
Interventions
Merit Medical Embospheres, Radiation Therapy
Device · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
50 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 29, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NCT03274687
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy
Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
229
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 188 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 29, 2026, 11:25 AM EDT
Completed Phase 1 Interventional

Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy

NCT00006044
View directory record Official record
Conditions
Prostate Cancer
Interventions
therapeutic testosterone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 29, 2026, 11:25 AM EDT
Not yet recruiting Not applicable Interventional

Effects of Exercise Prior to Radical Prostatectomy

NCT07746414
View directory record Official record
Conditions
Recovery, Post Prostatectomy
Interventions
High-intensity interval training (HIIT) exercise
Behavioral
Lead sponsor
Yale University
Other
Eligibility
35 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 29, 2026, 11:25 AM EDT
Terminated Not applicable Interventional Results available

Applications of Dual Energy CT in Patients With Osseous Metastases From Castrate-resistant Prostate Cancer

NCT03111914
View directory record Official record
Conditions
Dual Energy CT (DECT), Prostate Cancer
Interventions
Dual Energy Computed Tomography
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 29, 2026, 11:25 AM EDT
Completed Phase 1 Interventional

Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer

NCT00403221
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
RTVP-1 Gene
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2012 · Synced Oct 29, 2026, 11:25 AM EDT
Terminated Phase 3 Interventional Results available

Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer

NCT00809458
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vitamin E
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 29, 2026, 11:25 AM EDT
Terminated Phase 1 Interventional

PK and Dose Escalation and Expansion Study of DST-2970

NCT04291664
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone)
Drug
Lead sponsor
DisperSol Technologies, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Miami, Florida • New Orleans, Louisiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 29, 2026, 11:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers

NCT00984919
View directory record Official record
Conditions
Prostate Cancer
Interventions
high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
40 Years to 120 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 29, 2026, 11:25 AM EDT
Withdrawn Phase 2 Interventional

Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer

NCT02811809
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, IHT
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 29, 2026, 11:25 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

NCT05498272
View directory record Official record
Conditions
Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Interventions
Olaparib, LHRH agonist
Drug
Lead sponsor
Rana McKay, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
La Jolla, California • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 29, 2026, 11:25 AM EDT
Terminated Phase 1 Interventional

Study of rSIFN-co for Patients With Advanced Solid Tumors

NCT02464007
View directory record Official record
Conditions
Malignancies Including Melanoma, Kidney, Lung, Colorectal, Prostate, Neuroendocrine Tumor
Interventions
rSIFN-co
Biological
Lead sponsor
Sichuan Huiyang Life Science and Technology Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • Chicago, Illinois • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 29, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

NCT00558272
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Bone Neoplasms
Interventions
AZD0530, Zoledronic Acid
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Pleasant Hill, California • Sacramento, California • Middlebury, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 29, 2026, 11:25 AM EDT
Completed Phase 1 Interventional

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00026377
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, goserelin acetate, leuprolide acetate, SU5416, radiation therapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
Chicago, Illinois • LaGrange, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 29, 2026, 11:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA

NCT01147965
View directory record Official record
Conditions
Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
Interventions
Ad5 CEA Vaccine
Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Durham, North Carolina • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 29, 2026, 11:25 AM EDT